+612 9045 4394
 
CHECKOUT
Cardiac Arrhythmias : New Therapeutic Drugs and Devices :  New Therapeutic Drugs and Devices - Joel Morganroth

Cardiac Arrhythmias : New Therapeutic Drugs and Devices

New Therapeutic Drugs and Devices

By: Joel Morganroth (Editor), E. Neil Moore (Editor)

Hardcover

Published: December 2009
Ships: 7 to 10 business days
7 to 10 business days
RRP $609.99
$422.25
31%
OFF
or 4 easy payments of $105.56 with Learn more

Proceedings of the Symposium on New Drugs and Devices, held at Philadelphia, PA October 4 and 5, 1984

I Basic Considerations.- 1 What animal models are useful in selecting new antiarrhythmic drugs?.- 2 How to test for antiarrhythmic drugs.- 3 Initial evaluation of new antiarrhythmic agents in man: normal volunteers or patients?.- 4 Is there a rational basis for the modified classification of antiarrhythmic drugs?.- Panel Discussion: Basic considerations.- II Status of Specific Antiarrhythmic Agents.- 5 Procainamide, Quinidine, Disopyramide, Cibenzoline, Pirmenol - efficacy in the treatment of ventricular arrhythmias: current status and controversies.- 6 Mexiletine, Tocainide and Ethmozine: newer class I antiarrhythmic agents.- 7 Class IC antiarrhythmic agents: status - 1984.- 8 Role of beta-blocking agents in the treatment of ventricular arrhythmias.- 9 Status of class III antiarrhythmic drugs: Amiodarone, Bretylium and Sotalol.- Panel Discussion: Status of specific antiarrhythmic agents.- III Special Considerations and FDA Standards.- 10 Some thoughts on efficacy trials of antiarrhythmic agents: pitfalls of mimicking clinical practice.- 11 Use of a computer in the new drug evaluation process.- 12 Sudden cardiac death - failure or effect of antiarrhythmic drug therapy?.- 13 Sudden death as an end-point for the clinical evaluation of antiarrhythmic drugs.- 14 Holter/exercise and electrophysiologic methods forevaluating drug therapy for malignant ventricular arrhythmias: do we need both models?.- Panel Discussion: Special considerations and FDA standards.- IV New Antiarrhythmic Devices.- 15 DVI vs DDD pacemakers - proarrhythmic or antiarrhythmic?.- 16 Pacing for ventricular tachycardia.- 17 Termination of ventricular tachycardia by transvenous cardioversion.- 18 The automatic implantable cardioverter/defibrillator.- 19 New antiarrhythmia devices - FDA's requirements for effectiveness.- Panel Discussion: New antiarrhythmic devices.- V Evaluation Of Atrial Arrhythmias.- 20 Study designs to evaluate atrial arrhythmias are easy.- 21 Role of the autonomic nervous system in the generation of supraventricular tachyarrhythmias: clues to drug selection.- 22 Approaches to drug selection and serial drug testing.- Panel Discussion: Evaluation of atrial arrhythmias.- Participants.

ISBN: 9780898387162
ISBN-10: 0898387167
Series: Developments in Cardiovascular Medicine
Audience: Professional
Format: Hardcover
Language: English
Number Of Pages: 356
Published: December 2009
Publisher: Kluwer Academic Publishers
Country of Publication: US
Dimensions (cm): 23.5 x 15.5  x 2.2
Weight (kg): 1.54